Clinical Trial Update: Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) [Phase 2, Phase 3]

View source ↗

Summary

Pediatric Phase 2/3 trial evaluating vericiguat for heart failure due to left ventricular systolic dysfunction, assessing efficacy, safety, and pharmacokinetics…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Left Ventricular Systolic Dysfunction

Drugs mentioned

• Vericiguat (vericiguat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Heart Failure, Left Ventricular Systolic Dysfunction | Phase 2, Phase 3 | Status: RECRUITING